RCOG/FSRH respond to reports of 30,000 women’s periods affected after COVID-19 vaccine.
Selected adverse events reported after COVID-19 vaccination.
|Prevaccination interval 0 (16 wk)||Postvaccination interval 1 (1–16 wk)||Postvaccination interval 2 (17–34 wk)||P value for trend|
|Fisher exact test P value with adjustments for multiple comparisons|
|Women at risk of incident bleeding (N)||485,132||484,971||484,572|
|Incident PMB diagnoses|
|Incidence of PMB||0.39% (0.38–0.41)||0.47% (0.45–0.49)||0.43% (0.41–0.45)||.004||Pre vs Post 1, P<.001|
Pre vs Post 2, P=.012
Post 1 vs Post 2, P=.051
Pre vs (Post 1+Post 2), P<.001
- Menstrual changes after covid-19 vaccination.BMJ. 2021; 374: n2211
- RCOG/FSRH respond to reports of 30,000 women’s periods affected after COVID-19 vaccine.(Available at:)https://www.rcog.org.uk/news/rcogfsrh-respond-to-reports-of-30-000-women-s-periods-affected-after-covid-19-vaccine/Date: 2021Date accessed: May 1, 2022
- Selected adverse events reported after COVID-19 vaccination.(Available at:)https://www.cdc.gov/coronavirus/2019-ncov/vaccines/safety/adverse-events.htmlDate: 2022Date accessed: May 1, 2022
- Comparison of epidemiologic methods for active surveillance of vaccine safety.Vaccine. 2008; 26: 3341-3345
- Association between menstrual cycle length and coronavirus disease 2019 (COVID-19) vaccination: a U.S. cohort.Obstet Gynecol. 2022; 139: 481-489
Publication stageIn Press Journal Pre-Proof
The authors report no conflict of interest.
The study was funded by The Permanente Medical Group Physician Researcher Program.